Evidence map›Paper›PMID 31390266›Full record

ReviewAmerican journal of physiology. Renal physiology2019

Sphingosine-1-phosphate signaling in blood pressure regulation.

Suttira Intapad

Abstract readReview
In one paragraph

Review in American journal of physiology. Renal physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Sphingolipids and Chronic Kidney Disease.Journal of clinical medicine · 2024
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Suttira IntapadDepartment of Pharmacology Tulane University School of Medicine, New Orleans, Louisiana.

Funding

Tulane COBRE in Cardiometabolic Diseases Clinical Research CoreP20GM109036 · NIGMS · TULANE UNIVERSITY OF LOUISIANA · PI Ning Liu · 2016 to 2026
$25.3M
NIGMS NIH HHS P20 GM109036
6 · The paper itself

Abstract

Sphingolipids were originally believed to play a role only as a backbone of mammalian cell membranes. However, sphingolipid metabolites, especially sphingosine-1-phosphate (S1P), are now recognized as new bioactive signaling molecules that are critically involved in numerous cellular functions of multiple systems including the immune system, central nervous system, and cardiovascular system. S1P research has accelerated in the last decade as new therapeutic drugs have emerged that target the S1P signaling axis to treat diseases of the immune and central nervous systems. There is limited knowledge of the specific effects on cardiovascular disease. This review discusses the current state of knowledge regarding the role of S1P on the regulation of blood pressure, vascular tone, and renal functions.

Indexed as

Blood PressureSignal TransductionAnimalsArteriesHomeostasisHumansKidneyLysophospholipidsSphingosineSphingosine-1-Phosphate ReceptorsVasoconstrictionVasodilationLysophospholipidsSphingosinesphingosine 1-phosphateSphingosine-1-Phosphate Receptorsblood pressurerenal functionsphingosine-1-phosphatevascular tone

Identifiers

PMID31390266
PMCPMC6766635

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.